Cost-Effectiveness of Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain in Taiwan

Medicine & Life Sciences

• mirogabalin 100%
• Neuralgia 49%
• Taiwan 47%
• Quality-Adjusted Life Years 43%
• Cost-Benefit Analysis 41%
• Pain 27%
• Pregabalin 21%
• Health 15%
• Costs and Cost Analysis 14%
• Health Care Costs 14%
• Placebos 10%
• Network Meta-Analysis 10%
• Phase III Clinical Trials 9%
• National Health Programs 8%
• Therapeutics 7%
• Economics 6%
• Ligands 5%

Business & Economics

• Cost-effectiveness 66%
• Pain 55%
• Taiwan 36%
• Quality-adjusted Life Years 35%
• Health State 29%
• Incremental Cost 27%
• Cost-effectiveness Ratio 23%
• Robustness 13%
• Markov Model 8%
• Willingness-to-pay 8%
• National Health Insurance 6%
• Scenarios 6%
• Clinical Trials 6%
• Resource Use 5%
• Meta-analysis 5%
• Efficacy 4%
• Economic Analysis 4%
• Costs 2%

Social Sciences

• pain 45%
• Taiwan 39%
• life years 35%
• costs 26%
• health 9%
• scenario 7%
• utility value 7%
• willingness to pay 6%
• Clinical Trials 5%
• health insurance 5%
• dollar 5%
• expert 3%
• resources 2%
• economics 2%
• literature 2%